Phase I-Ib Study of the Safety and Immunobiology of Prophylactic Lymphocyte and Natural Killer Cell Infusion Following Allogeneic Hematopoietic Cell Transplantation to Prevent Graft-versus-Host Disease

The primary objective of this Phase I-Ib clinical trial is to evaluate the **safety** and **immunobiology** of prophylactic infusion of lymphocytes and NK cells following allogeneic hematopoietic cell transplantation (Allo-HCT) in patients at risk of developing **graft-versus-host disease**. This study is clinically relevant as it aims to enhance the understanding of immune cell therapy in preventing or mitigating the effects of graft-versus-host disease, a significant complication associated with Allo-HCT. The trial seeks to determine the potential benefits and risks associated with this prophylactic approach, thereby contributing to improved patient outcomes in the context of hematopoietic cell transplantation.

The clinical trial involves participants diagnosed with **graft-versus-host disease**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been disclosed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the safety and immunobiology of prophylactic infusion of lymphocytes and **NK cells** following allogeneic hematopoietic cell transplantation (Allo-HCT) in patients with **graft-versus-host disease**. This trial is structured as a Phase I-Ib study, which is a preliminary phase aimed at assessing safety and biological activity. The trial is expected to commence recruitment on June 2, 2025, and is projected to conclude by May 31, 2026. The study employs a randomized, double-blind, controlled design to ensure unbiased results and reliable data collection.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health status, assess the safety of the intervention, and collect data on immunobiological responses. The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather conclusive data on the trial's primary and secondary endpoints.

The expected duration of participant involvement in the trial is approximately one year, contingent upon individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the intervention, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements to ensure participant safety and data integrity throughout the study period.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on June 2, 2025, with an estimated completion date of May 31, 2026. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, ensuring adherence to rigorous scientific standards. The trial's design and execution will align with the expectations of clinical trial protocols, focusing on objective and scientifically accurate assessments. The trial's primary aim is to generate reliable data on the efficacy of the intervention under investigation, contributing to the broader understanding of its potential therapeutic benefits.